Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ismat Lotia Farrukh; Nathalie Lachenal; Malik M Adenov; Saman Ahmed; Yerkebulan Algozhin; Sylvine Coutisson; Epifanio Sánchez Garavito; Catherine Hewison; David Holtzman; Helena Huerga; Aleeza Janmohamed; Palwasha Y Khan; Gamarly Leblanc Jacques; Nino Lomtadze; Nara Melikyan; Carole D Mitnick; Gulnaz Mussabekova; Elna Osso; Sara Perea; Fauziah Asnely Putri; Mahmud Rashidov; Michael L Rich; Yekaterina Sakhabutdinova; Kwonjune J Seung; Assel Stambekova; Dante Vargas Vásquez; Molly F Franke; Uzma Khan

doi:10.1093/cid/ciad445

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Clin Infect Dis. 2024 Jan 25;78(1):144-148. doi: 10.1093/cid/ciad445.

Authors

Ismat Lotia Farrukh¹, Nathalie Lachenal², Malik M Adenov³, Saman Ahmed¹, Yerkebulan Algozhin⁴, Sylvine Coutisson², Epifanio Sánchez Garavito⁵, Catherine Hewison⁶, David Holtzman⁷, Helena Huerga⁸, Aleeza Janmohamed¹, Palwasha Y Khan^{1

9}, Gamarly Leblanc Jacques¹⁰, Nino Lomtadze¹¹, Nara Melikyan¹², Carole D Mitnick^{13

14}, Gulnaz Mussabekova³, Elna Osso¹³, Sara Perea¹⁵, Fauziah Asnely Putri¹⁶, Mahmud Rashidov⁴, Michael L Rich^{14

17}, Yekaterina Sakhabutdinova⁴, Kwonjune J Seung^{14

17}, Assel Stambekova⁴, Dante Vargas Vásquez¹⁸, Molly F Franke¹³, Uzma Khan¹

Affiliations

¹ Interactive Research and Development Pakistan, Karachi, Pakistan.
² Pharmacovigilance Unit, Médecins Sans Frontières, Geneva, Switzerland.
³ National Scientific Center of Phthisiopulmonology, Ministry of Health, Republic of Kazakhstan, Almaty, Kazakhstan.
⁴ Partners In Health, Almaty, Kazakhstan.
⁵ Centro de Investigación de Enfermedades Neumológicas, Hospital Nacional Sergio Bernale, Lima, Peru.
⁶ Medical Department, Médecins Sans Frontières, Paris, France.
⁷ Partners In Health, Maseru, Lesotho.
⁸ Field Epidemiology Department, Epicentre, Paris, France.
⁹ London School of Hygiene & Tropical Medicine, London, United Kingdom.
¹⁰ Zanmi Lasante, Cange, Haiti.
¹¹ Surveillance and Strategic Planning, Ministry of Health, Tbilisi, Georgia.
¹² Field Epidemiology Department, Epicentre, Yerevan, Armenia.
¹³ Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
¹⁴ Partners In Health, Boston, Massachusetts, USA.
¹⁵ Socios En Salud Sucursal Peru, Lima, Peru.
¹⁶ Interactive Research and Development Global, Jakarta, Indonesia.
¹⁷ Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹⁸ Centro de Investigación, Hospital Nacional Hipólito Unanue, Lima, Peru.

Abstract

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

Keywords: drug resistance; outcome; pregnancy; treatment; tuberculosis.

MeSH terms

Antitubercular Agents* / therapeutic use
Clinical Protocols
Diarylquinolines / therapeutic use
Female
Humans
Infant, Newborn
Live Birth
Pregnancy
Treatment Outcome
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents
Diarylquinolines

Grants and funding

R01 AI146095/AI/NIAID NIH HHS/United States